Immix Biopharma, Inc. (NASDAQ:IMMX) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Immix Biopharma, Inc. (NASDAQ:IMMX) has been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $24.29.

IMMX has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a research note on Thursday. Mizuho increased their price objective on Immix Biopharma from $15.00 to $26.00 and gave the stock an “outperform” rating in a report on Tuesday, September 15th. Citigroup reissued a “market outperform” rating on shares of Immix Biopharma in a research report on Wednesday, September 30th. HC Wainwright boosted their target price on Immix Biopharma from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Finally, Morgan Stanley set a $20.00 target price on Immix Biopharma in a research report on Tuesday.

Institutional Trading of Immix Biopharma

A number of institutional investors have recently added to or reduced their stakes in IMMX. Jupiter Topco LLC bought a new position in shares of Immix Biopharma during the 2nd quarter valued at $100,816,000. Janus Henderson Group PLC lifted its stake in shares of Immix Biopharma by 22.5% in the 1st quarter. Janus Henderson Group PLC now owns 4,802,002 shares of the company’s stock valued at $43,698,000 after purchasing an additional 880,434 shares during the last quarter. BlackRock Inc. bought a new stake in Immix Biopharma in the second quarter worth $30,827,000. Opaleye Management Inc. bought a new stake in Immix Biopharma in the second quarter worth $24,177,000. Finally, Wellington Management Group LLP acquired a new position in Immix Biopharma during the second quarter worth $15,191,000. 11.26% of the stock is currently owned by institutional investors and hedge funds.

Immix Biopharma Stock Performance

Shares of IMMX opened at $8.22 on Tuesday. The company has a market capitalization of $588.06 million, a PE ratio of -9.34 and a beta of 0.24. The company’s 50 day moving average price is $11.71 and its 200 day moving average price is $10.22. Immix Biopharma has a 52 week low of $2.71 and a 52 week high of $15.10.

Immix Biopharma (NASDAQ:IMMX) last released its earnings results on Friday, August 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). On average, equities analysts forecast that Immix Biopharma will post -0.74 earnings per share for the current fiscal year.

About Immix Biopharma

Immix Biopharma, Inc is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer and autoimmune diseases. The company’s research centers on treatments designed to use a patient’s immune system to identify and attack disease-related cells.

Its lead product candidate is NXC-201, an investigational autologous CAR T-cell therapy targeting B-cell maturation antigen (BCMA), a protein found on malignant plasma cells. NXC-201 is being evaluated in clinical studies involving patients with relapsed or refractory AL amyloidosis and multiple myeloma, including the company’s NEXICART-1 study.

Immix Biopharma was founded in 2012 and is based in Los Angeles, California.